Kymera Therapeutics, Inc.
KYMR
Rang in aandelen
#2179
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Aandeelprijs
$114.06
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$9.38B
Verandering (1 dag)
5.54%
Verandering (1 jaar)
95.57%
Land
US
Handel Kymera Therapeutics, Inc. (KYMR)
Categorie
Healthcare
P/S-ratio voor Kymera Therapeutics, Inc. (KYMR)
P/S-ratio op October 2026 TTM: 83.70
Volgens de meest recente financiële rapporten en aandelenkoers van Kymera Therapeutics, Inc. is de huidige P/S-ratio (TTM) 83.70. Eind 2023 had het bedrijf een P/S-ratio van 18.91.
P/S-ratiohistoriek voor Kymera Therapeutics, Inc. van 2018 tot 2026
P/S-ratio aan het einde van elk jaar
| Jaar | P/S-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 83.70 | 30.50% |
| 2024 | 64.14 | 239.21% |
| 2023 | 18.91 | -34.23% |
| 2022 | 28.75 | -31.28% |
| 2021 | 41.83 | -48.46% |
| 2020 | 81.17 | -83.92% |
| 2019 | 504.79 | 0.00% |
| 2018 | 0.00 | 0.00% |
P/S-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/S-ratio | Verschil in P/S-ratio | Land |
|---|---|---|---|
| 10.02 | -88.03% |
US
|
|
| 40.55 | -51.55% |
US
|
|
| 3.96 | -95.27% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -87.88% |
NL
|
